The Grapefruit Juice Effect Psychopharma
The Grapefruit Juice Effect Psychopharma
What is now a vast literature on the interaction effects of grapefruit juice with various
drugs can be traced back to 1989 when a team of researchers investigating the interaction of
ethanol and folodipine accidentally discovered that grapefruit juice, used with the intention of
masking the taste of ethanol, increased the blood levels of felodipine (Bailey, Spence, Edgar,
Bayliff & Arnold, 1989). This discovery drew the attention of the drug metabolism
researchers; and further studies focusing on the interaction of grapefruit and its juice with
various drugs were conducted. As a result of these studies, it is now known that something in
grapefruit inhibits an enzyme in the wall of the intestine that is responsible for the breakdown
of a number of medicines (The People’s Pharmacy, 2002). This review aims to elaborate on
the mechanisms underlying this interaction while focusing especially on the effects on
psychopharmaceutical drugs.
Studies, so far, have reported that grapefruit juice increases oral bioavailability of
many drugs including cyclosporine, terfenadine, felodipine, simvastatin and nifedipine. (e.g.
Mehrsai, Pourmand, Mansour, Zand & Rezaali, 2003; Clifford et.al., 1996; Lown et al., 1997;
Lilja, Neuvonen & Neuvonen, 2003; Adigun & Mudasiru, 2002). A common point of all these
drugs is that they are primarily metabolized by Cychtrome P450 3A4 (CYP3A4).
Consequently, most of the research on the grapefruit juice effect focuses on the modulation of
this cytochrome as it relates to elevated blood levels of various drugs. Cycthrome P450 (CYP)
enzymes system refers to a group of enzymes that are involved in drug activation and
metabolism (Engin et.al., 2009). CYP3A4, a member of the superfamily of cytochrome P450
enzymes, is responsible for the oxidation of many xenobiotics. Abundant in especially the
liver and the intestine, CYP3A4 is also reportedly the substrate of almost half of the marketed
drugs (Su, Ueng, Dung, Reddy & Wu, 2007).
The main theory on how the grapefruit juice effect occurs is based on the research
implications which indicate that a substance yet to be identified in the grapefruit directly
inhibits the activities of the cychtochrome P4503A4. This, in turn, results in an obstruction in
the breakdown process, impairs first pass metabolism, and eventually leads to higher blood
levels of the administered substance (Maskalyk, 2002). Thus, two conditions should be met
for a drug to interact with grapefruit juice: (1) the drug substrate must be predominantly
metabolized by CYP3A4; and (2) it must undergo first pass metabolism (Shimomura,
Wanwimolruk & Chen, 2003). In addition, this interaction effect is reported to be partially
irreversible. That is, because the effect of a single 8-oz glass of grapefruit juice can last for 24
Grapefruit Juice 3
to 48 hours, taking the drug at a separate time from drinking the juice may still result in the
interaction effect (Wilkinson, 2005).
The level and/or manifestations of this effect, on the other hand, are shown to be
dependent on a number of factors including the grapefruit juice consumption patterns,
characteristics of the drug and form of drug administration. McCloskey, Zaiken and Courls
(2008) argue that repeated consumption of grapefruit juice increases the inhibitory effect, and
results in enhancement of the extent of interaction. The level of interaction can also vary
depending on some characteristics of the drugs. For example, it has been reported that even
though both nisoldipine and amlodipine are dihydropyridines; the former is more susceptible
to the grapefruit effect because it has a very low innate bioavalibility (Bailey, Malcolm,
Arnold & Spence, 1998). In addition, comparative studies have demonstrated that grapefruit
juice is only effective in orally administered drugs as compared to intravenous forms of
administration (e.g. Kupferschmidt, Fattinger, Ha, Follath & Krähenbühl, 1998). Similarly,
Bailey (2002) reports that no interactions would be expected from simultaneous intake of
grapefruit juice with parenterally or transdermally administered drugs. This, as a side note, is
mainly based on (and the basis of) the research indicating that active ingredient of the
grapefruit juice primarily functions on the intestinal, rather than hepatic, activities of CYP3A4
(Chan, Nguyen, Miller & Harris, 1998).
Elbe (n.d.) lists several medications that should be avoided or to be used with caution
with grapefruit juice. A number of these medications are widely used psychopharmaceutical
drugs; buspirone (BuSpar), bupropion (Zyban), carbamazepine (Tegretol), clomipramine
(Anafranil), diazepam (Valium), quetiapine fumarate (Seroquel), midazolam (Versed),
sertraline (Zoloft), trazodone (Desyrel), and triazolam (Halcion). The listed drugs can be
grouped under the main categories of antidepressants, anxiolytics, mood stabilizers, and
antipsychotics. These drug types are among the most frequently prescribed pharmaceuticals.
For example, one study reports that of the 2.4 billion drugs prescribed in the United States,
1.8 million were antidepressants (Cohen, 2005). Similarly, it has also been reported that about
12.5% of the United States population uses prescribed anxiolytics (Suzuki, Sola & Akinsoto,
2006). Consequently, considering the wide prescription rates, it becomes clinically vital to
further elaborate on what effects may surface when these drugs taken with grapefruit juice.
When grapefruit juice is taken with antidepressants such as amitripytline, sertraline,
trazodone, nefazodone, and clomipramine; it has been shown to increase plasma
concentrations of these drugs. Lee and colleagues (1999) conducted an in-vivo and in-vitro
study on grapefruit-juice setraline interaction, and reported that grapefruit juice causes a 50%
Grapefruit Juice 4
of action can be described for specific drugs, clinicians may be called to be cautious on the
enhancing effects of the grapefruit juice in the prescription process of especially the already
listed medication. Furthermore, informing the patients on this effect may be helpful in
preventing undesired consequences of elevated plasma levels.
Grapefruit Juice 6
References
Kupferschmidt, H.H.T., Ha, H.R., Ziegler, W.H., Meier, P.H., & Krähenbühl, S. (1995).
Interaction between grapefruit juice and midazolam in humans. Clinical
Pharmacology & Therapeutics 58, 20-28.
Kupferschmidt, H.H.T., Fattinger, K.E., Ha, H.R., Follath, F., & Krähenbühl, S. (1998).
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir
in man. Br J Clin Pharmacol. 45 (4), 355-359.
Lee, A.J., Chan, W.K., Harralson, A.F., Baffum, J., & Cyrstal Bui, B-C. (1999). The effects of
grapefruit juiceo n sertraline metabolism: An in vitro and in vivo study. Clinical
Therapeutics 21 (11), 1890-1899.
Lilja, J.J., Kivistoe, K.T., Backman, J.T., Lamberg, T.S., & Neuvonen, P.J. (1998). Grapefruit
juice substantially increases plasma concentrations of buspirone. Clin Pharcol Ther
64, 655-660.
Lilja, J.J., Neuvonen, M., & Neuvonen, P.J. (2003). Effects of regular consumption of
grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58 (1),
56-60.
Lown, K.S., Bailey, D.G., Fontana, R.J., Janardan, S.K., Adair, C.H., Fortlage, L.A., Brown,
M.B., Guo, W., & Watkins, P.B. (1997). Grapefruit juice increases felodipine oral
availability in humans by decreasing intestinal CYP3A protein expression. Journal of
Clinical Investigation 99 (10), 2454-2553.
Maskalyk, J. (2002). Grapfruit juice: Potentian drug interactions. Canadian Medical
Association Journal 167 (3), 279-280.
McCloskey, W.W., Zaiken, K., & Couris, R.R. (2008). Clinically significant grapefruit juice-
drug interactions. Nutrition Today 43 (1), 19-26.
Mehrsai, A.R., Pourmand, G., Mansour, D., Zand, S., & Rezaali, A. (2003). Effect of
grapefruit juice on serum concentration of cyclosporine in Iranian renal transplant
patients. Transplantation Proceedings 35, 2739-2741.
Keltner, N.L. (2002). Psychotrophic drug interactions with grapefruit juice: Biological
perspectives. Perspectives in Psychiatric Care 38 (1), 31-34.
Oesterheld J., & Kallepalli, B.R. (1997). Grapefruit juice and clomipramine: Shifting
metabolitic ratios. Journal of Clinical Psychopharmacology 17, 62–63
Shimomura, S., Wanwimolruk, S., & Chen, J.J. (2003). Drug interactions with grapefruit
juice: An evidence based overview. Pharmacy Times. Retrieved October 28, 2009
from https://secure.pharmacytimes.com/lessons/200303-02.asp
Grapefruit Juice 8
Su, C-R., Ueng, Y-F., Dung, N.X., Reddy, V.B., & Wu, T-S. (2007). Cytochrome P3A4
inhibitors and other constituents of fibraurea tinctoria. J.Nat.Prod. 70, 1930-1922.
Suzuki, J., Sola, C.L., & Akinsoto, O.P.A. (2006). Sedative, hypnotic, anxiolytic use
disorders. Retrieved October 25, 2009 from
http://emedicine.medscape.com/article/290585-overview
The People’s Pharmacy. (2002). Graedons’ guide to grapefruit interactions. Retrieved October
25, 2009 from www.healthcentral.com/static/pp/pdf_guides/gfruit02.pdf
Totic, S., Marinkovic, D., & Marjanovic, M. (2008). Antiepileptic mood stabilizers
(carbamezepine and valproate) in acute-phase psychotic bipolar mania treatment.
European Neuropsychopharmacology 18, 367-368.
Vandel, P., Regina, W., Reix, I., Vandel, S., Sechter, D., & Bizouard, P. (1999). Grapefruit
juice as a contraindication? An approach to psychiatry. L’Encéphale 25 (1), 67-71.
Wilkinson, G.R. (2005). Drug metabolism and variability among patients in drug response.
The New England Journal of Medicine 352, 2211-2221.